PMID- 31190873
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Efficacy and tolerability of stereotactic body radiotherapy for lung metastases 
      in three patients with pediatric malignancies.
PG  - 3723-3727
LID - 10.2147/OTT.S194812 [doi]
AB  - Purpose: To report a case series of 3 pediatric patients treated with 
      Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Patients and 
      methods: Three patients (ages 9, 11, and 21) received SBRT for rhabdoid tumor, 
      Ewing sarcoma, and Wilms tumor histologies, respectively. SBRT doses were 
      37.5-50 Gy in 3-5 fractions treating twelve lesions. Results: Three patients 
      (ages 9, 11, and 21) received photon SBRT for pulmonary metastases. The patients 
      were as follows: 1) 21-year-old male with favorable histology Wilms tumor and 1 
      lesion treated, 2) 11-year-old female with Ewing sarcoma and 1 lesion treated for 
      relapse after previous whole lung radiation (15 Gy), and 3) 9-year-old female 
      with rhabdoid tumor of the left thigh with 10 lesions treated over a two-year 
      period. Median dose delivered was 40 Gy (range, 37.5-50 Gy), delivered in a 
      median of 4 fractions (range, 4-5) of a median of 10 Gy per fraction (range, 
      9.4-10 Gy). Within a minimum follow-up of 1.9 years (range 1.9-4 years), local 
      control for all 13 treated metastases is 100% without any observed acute 
      toxicities. One possible late toxicity (grade 2 rib fracture) developed 1.3 years 
      following SBRT for treatment of a peripheral lesion (rhabdoid tumor) in an area 
      of disease progression and was managed conservatively. Two patients are surviving 
      2.9 years (Wilms tumor) and 1.9 years (Ewing sarcoma) after SBRT, and one 
      (rhabdoid tumor) expired 2 years after her final course (4 years after initial 
      SBRT). Two patients (rhabdoid tumor and Ewing sarcoma) suffered disease 
      progression outside of the treated lesions and one patient (Wilms tumor) is 
      without evidence of disease and has not required whole lung irradiation or 
      further systemic therapy. Conclusion: SBRT appears effective and well tolerated 
      for pediatric lung metastases, however further studies are warranted.
FAU - Deck, Jared
AU  - Deck J
AD  - Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, 
      USA.
FAU - Eastwick, Gary
AU  - Eastwick G
AD  - Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, 
      USA.
FAU - Sima, Jody
AU  - Sima J
AD  - Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA.
FAU - Raymond, Amanda
AU  - Raymond A
AD  - Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, 
      USA.
FAU - Bogart, Jeffrey
AU  - Bogart J
AD  - Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, 
      USA.
FAU - Aridgides, Paul
AU  - Aridgides P
AD  - Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20190515
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6526915
OTO - NOTNLM
OT  - Ewing's sarcoma
OT  - SBRT
OT  - Wilms tumor
OT  - lung metastases
OT  - pediatric oncology
OT  - rhabdoid tumor
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/14 06:00
MHDA- 2019/06/14 06:01
PMCR- 2019/05/15
CRDT- 2019/06/14 06:00
PHST- 2018/11/15 00:00 [received]
PHST- 2019/03/27 00:00 [accepted]
PHST- 2019/06/14 06:00 [entrez]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2019/06/14 06:01 [medline]
PHST- 2019/05/15 00:00 [pmc-release]
AID - 194812 [pii]
AID - 10.2147/OTT.S194812 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 May 15;12:3723-3727. doi: 10.2147/OTT.S194812. 
      eCollection 2019.